Viberzi (eluxadoline) is approved for use in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Viberzi works by activating opioid receptors in the gut to decrease bowel contractions, which leads to less diarrhea. It can also help to ease stomach-area or abdomen pain and improve stool consistency. In March 2017 this … [Read more...]
FDA Warns of Serious Pancreatitis Risk in Some Patients Taking Viberzi
In March of this year, the FDA released a Drug Safety Communication concerning the increased risk of serious pancreatitis in patients without a gallbladder who use the irritable bowel syndrome drug, Viberzi (eluxadoline). Viberzi is a relatively new drug manufactured by Allergan used to treat irritable bowel syndrome in adults when the main … [Read more...]